Disease · MONDO_0001166

nephritis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. nephritis. Diseases, record MONDO_0001166. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001166

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: nephritis; Open Targets
Open Targets ID: MONDO_0001166; Open Targets
Other names: inflammation of kidney, kidney inflammation; Open Targets
Disease Ontology: DOID:10952; Disease Ontology
MeSH: D009393; MeSH
NCI Thesaurus: C26833; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 2 of its 13 drugs, from ClinicalTrials.gov and TTD; Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OCRELIZUMAB	CHEMBL2108041	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BINDARIT	CHEMBL2107549	Small molecule	Phase 3	TTD	1	0	0	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
FLUDARABINE	CHEMBL1568	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
FILGRASTIM	CHEMBL1201567	Protein	Phase 2	ClinicalTrials.gov	2	2	1	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ROLAFAGREL	CHEMBL2107064	Small molecule	Phase 2	TTD	1	0	0	Drugs and targets
ALEMTUZUMAB	CHEMBL1201587	Antibody	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
LENOGRASTIM	CHEMBL2109128	Protein	Phase 1	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets18

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Phase 2	https://conductscience.org/library/genes/1441	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	2	B-lymphocyte antigen CD20 binding agent	Phase 3	https://conductscience.org/library/genes/931	Drugs and targets
CD52	CAMPATH-1 antigen	1	CAMPATH-1 antigen inhibitor	Phase 1	https://conductscience.org/library/genes/1043	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
POLA1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Investigational new drug	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Investigational new drug	https://conductscience.org/library/genes/23649	Drugs and targets
POLD1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Investigational new drug	https://conductscience.org/library/genes/5424	Drugs and targets
POLD2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Investigational new drug	https://conductscience.org/library/genes/5425	Drugs and targets
POLD3	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Investigational new drug	https://conductscience.org/library/genes/10714	Drugs and targets
POLD4	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Investigational new drug	https://conductscience.org/library/genes/57804	Drugs and targets

1 to 10 of 18

See all 18 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00626197	A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)	Phase 3	381	2020-12-22	Lupus Nephritis, Systemic Lupus Erythematosus	OCRELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00076752	Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus	Phase 2	9	2014-06-10	Lupus Erythematosus, Systemic	CYCLOPHOSPHAMIDE, FILGRASTIM, FLUDARABINE, METHYLPREDNISOLONE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT06152172	CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101	Phase 1	24		Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis	CYCLOPHOSPHAMIDE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT00001676	Cyclophosphamide and Fludarabine to Treat Lupus Nephritis	Phase 1	15		Glomerulonephritis, Lupus Nephritis, Systemic Lupus Erythematosus	CYCLOPHOSPHAMIDE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT00278590	Allogeneic Stem Cell Transplantation in Systemic Lupus Erythematosus	Phase 1	0		Systemic Lupus Erythematosus	ALEMTUZUMAB, CYCLOPHOSPHAMIDE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21873334	RESULT	1	PubMed
34875023	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001166

GET https://conductscience.org/api/diseases/v1/MONDO_0001166/drugs

API reference For AI assistants